Literature DB >> 16998760

IVIG therapy in neurological disorders of childhood.

Juan J Archelos1, Franz Fazekas.   

Abstract

There is growing evidence that intravenous immunoglobulins (IVIG) are effective in some neuroimmunological disorders of childhood. This short review summarizes the evidence-based indications and recommendations of IVIG therapy in these disorders. Despite considerable efforts to define the role and mechanisms of IVIG, more clinical studies are needed to further explore the therapeutic potential of IVIG in childhood diseases of the nervous system and muscle.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16998760     DOI： 10.1007/s00415-006-5014-y

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


  61 in total

1.  Parainfectious opsoclonus-myoclonus syndrome: high dose intravenous immunoglobulins are effective.

Authors:  K Glatz; H-M Meinck; B Wildemann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-02       Impact factor: 10.154

2.  Immune globulins are effective in severe pediatric Guillain-Barré syndrome.

Authors:  E Shahar; Z Shorer; C M Roifman; Y Levi; N Brand; S Ravid; E G Murphy
Journal:  Pediatr Neurol       Date:  1997-01       Impact factor: 3.372

3.  Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus.

Authors:  L Bataller; F Graus; A Saiz; J J Vilchez
Journal:  Brain       Date:  2001-02       Impact factor: 13.501

4.  Outcome of severe Guillain-Barré syndrome in children: comparison between untreated cases versus gamma-globulin therapy.

Authors:  Eli Shahar; Maxim Leiderman
Journal:  Clin Neuropharmacol       Date:  2003 Mar-Apr       Impact factor: 1.592

Review 5.  IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.

Authors:  Isabel Illa
Journal:  J Neurol       Date:  2005-05       Impact factor: 4.849

Review 6.  Guillain-Barré syndrome in childhood.

Authors:  Monique M Ryan
Journal:  J Paediatr Child Health       Date:  2005 May-Jun       Impact factor: 1.954

7.  Interferon-beta treatment in patients with childhood-onset multiple sclerosis.

Authors:  Y Mikaeloff; T Moreau; M Debouverie; J Pelletier; C Lebrun; O Gout; J M Pedespan; C Van Hulle; P Vermersch; G Ponsot
Journal:  J Pediatr       Date:  2001-09       Impact factor: 4.406

8.  Outcome of severe encephalomyelitis in children: effect of high-dose methylprednisolone and immunoglobulins.

Authors:  Eli Shahar; Jameel Andraus; David Savitzki; Giora Pilar; Nathaniel Zelnik
Journal:  J Child Neurol       Date:  2002-11       Impact factor: 1.987

9.  Natural history and treatment effects in Guillain-Barré syndrome: a multicentre study.

Authors:  R Korinthenberg; J S Mönting
Journal:  Arch Dis Child       Date:  1996-04       Impact factor: 3.791

10.  Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome.

Authors:  Elizabeth D Tate; Tyler J Allison; Michael R Pranzatelli; Steven J Verhulst
Journal:  J Pediatr Oncol Nurs       Date:  2005 Jan-Feb       Impact factor: 1.636
View more
  2 in total

Review 1.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

Review 2.  Neurological complications associated with Covid-19; molecular mechanisms and therapeutic approaches.

Authors:  Mohammad Mahboubi Mehrabani; Mohammad Sobhan Karvandi; Pedram Maafi; Mohammad Doroudian
Journal:  Rev Med Virol       Date:  2022-02-09       Impact factor: 11.043
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.